Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Figure 4

Ex vivo activity pattern of VLX40. (A) The ex vivo response rate in a panel of primary cultures of patient tumor cells (PCPTC) representing a range of diagnoses (n = 98) is shown. The concentrations used were 3.4 μM of VLX40 and 1 μM of vincristine. See material and methods for details. (B) The solid tumor/hematological tumor activity ratio (S/H ratio) is displayed for VLX40 and six standard agents (n = 99). (C) The IC50 ratio between CLL (n = 9) and PBMC (n = 4) is shown for VLX40 and six standard drugs. (D) Caspase-3 induction in multicellular spheroids prepared from HCT116 colon carcinoma cells. Multicellular spheroids were treated for 24 h, fixed, sectioned and stained for active caspase-3. Note the induction of apoptosis preferentially at peripheral cell layers.

Back to article page